Proteostasis Therapeutics (PTI) Earns Coverage Optimism Score of 0.05
Media headlines about Proteostasis Therapeutics (NASDAQ:PTI) have been trending somewhat positive on Sunday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Proteostasis Therapeutics earned a news impact score of 0.05 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.0750883220003 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Proteostasis Therapeutics (NASDAQ PTI) traded up $0.24 during midday trading on Friday, hitting $3.35. 346,925 shares of the stock were exchanged, compared to its average volume of 712,824. Proteostasis Therapeutics has a 52 week low of $1.41 and a 52 week high of $14.36. The company has a market cap of $110.93 and a P/E ratio of -1.52.
Several brokerages have commented on PTI. Robert W. Baird raised their price target on shares of Proteostasis Therapeutics from $13.00 to $25.00 and gave the company an “outperform” rating in a report on Tuesday, December 12th. Leerink Swann raised their price target on shares of Proteostasis Therapeutics from $6.00 to $8.00 in a report on Tuesday, December 12th. Zacks Investment Research raised shares of Proteostasis Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, February 14th. ValuEngine downgraded shares of Proteostasis Therapeutics from a “sell” rating to a “strong sell” rating in a report on Sunday, December 31st. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 price target on shares of Proteostasis Therapeutics in a report on Tuesday, December 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. Proteostasis Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $16.00.
About Proteostasis Therapeutics
Proteostasis Therapeutics, Inc is a biopharmaceutical company. The Company is engaged in discovery and development of therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. It has developed the Disease Relevant Translation (DRT) technology platform, a drug screening approach for identifying highly translatable therapeutics based on predictive and functionally pertinent phenotypic assays and disease relevant models.
Receive News & Ratings for Proteostasis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteostasis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.